Abstracts tagged "population studies"

Abstract Number: 0220 • ACR Convergence 2022
Social Media Use in Academic Rheumatology
Jorena Lim and Kathryn Dao, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Social media (SM) in medicine has evolved to become mainstream, and its use encouraged in medical education, research, and clinical practice. SM can enhance…
Abstract Number: 1976 • ACR Convergence 2022
Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
Amar Suwal¹, Biraj Shrestha², Ibiyemi Oke² and Anthony Donato², ¹Reading Hospital, Tower Health, Reading, PA, ²reading hospital- tower health, Reading, PA
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a higher burden of cardiovascular diseases (CVDs) than the general population, with most deaths resulting from myocardial infarctions.…
Abstract Number: 0389 • ACR Convergence 2022
Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-based Study
Lihi Eder¹, Idit Lavi², Amir Haddad³, Nili Stein⁴, Ilan feldhamer⁵, ARNON DOV COHEN⁵, Walid Saliba² and Devy Zisman², ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Carmel Medical Center, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel, ⁵Clalit Health Services, Tel Aviv, Israel
Background/Purpose: We assess the effectiveness of COVID-19 vaccination in preventing SARS-CoV2 infection and COVID-19 hospitalizations in patients with psoriatic disease (PsD) and non-psoriatic controls, and…
Abstract Number: 2220 • ACR Convergence 2022
Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study
YoungEun Kim¹, Ye-Jee Kim², Seonok Kim², Soo Min Ahn¹, Ji Seon Oh³, Yong Gil Kim¹, Chang Keun Lee¹, Bin Yoo¹, Sang Hyoung Park⁴ and Seokchan Hong¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea, ⁴Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors are known to increase the risk of herpes zoster (HZ) reactivation; however, studies on the risk of HZ recurrence when…
Abstract Number: 1024 • ACR Convergence 2021
Medical Care Seeking Is Frequent and Associated with Overuse of Low-Value Care for Low Back Pain in Portugal: Results from a Nationwide Population-Based Study
Luís Antunes Gomes¹, Eduardo Brazete Cruz², Ana Rita Henriques¹, Jaime Branco³, Helena Canhão⁴ and Ana Maria Rodrigues³, ¹EpiDoC Unit, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ²Comprehensive Health Research Centre (CHRC), Setubal, Portugal, ³EpiDoC Unit, CEDOC, Nova Medical School, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ⁴EpiDoC Unit, Comprehensive Health Research Centre (CHRC), Lisboa, Portugal
Background/Purpose: Low back pain (LBP) constitutes an important cause of disability and morbidity in general population. Appropriate care for LBP includes non-pharmacological interventions based on…
Abstract Number: 1046 • ACR Convergence 2021
Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea
SE RIM CHOI¹, Anna Shin², Joo Young Shin³, Hokyung Choung³, You-Jung Ha², Yun Jong Lee⁴, Eun bong Lee¹, Jin Kyun Park¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Department of Ophthalmology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁴Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
Background/Purpose: To examine the risk of ocular comorbidities in a nation-wide cohort of patients with Behçet’s disease (BD) compared to general population in Korea.Methods: We…
Abstract Number: 1057 • ACR Convergence 2021
Impact of Osteoarthritis in Younger Adults
Elizabeth Badley¹, Jessica Wilfong² and Anthony Perruccio¹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Shcroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: OA is a disease frequently perceived as a disease of the elderly and an inevitable result of aging. Consequently, epidemiological and clinical studies of…
Abstract Number: 1121 • ACR Convergence 2021
Association of Healthcare Costs and Utilization with Increasing Severity of Pain in Osteoarthritis Patients: An 18-Year Retrospective Study
Jove Graham¹, Tonia Novosat¹, Haiyan Sun¹, Brian Piper¹, Joseph Boscarino¹, Melissa Kern¹, Vanessa Duboski¹, Eric Wright¹, Craig Beck², Rebecca Robinson³, Edward Casey⁴, Jerry A. Hall³ and Patricia Schepman⁴, ¹Geisinger, Danville, PA, ²Pfizer, Inc., London, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer, Inc., New York, NY
Background/Purpose: Osteoarthritis (OA) is a disease with complex pathogenesis, and it is important to understand a patient's level of severity in order to plan and…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…
Abstract Number: 1286 • ACR Convergence 2021
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
Claudia Mendoza-Pinto¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Pamela Munguía-Realpozo² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Marked regional variation in systemic lupus erythematosus (SLE) mortality may be due to different spectra of local environmental factors. There have been no large…
Abstract Number: 1579 • ACR Convergence 2021
Phenome-Wide Association of Gout Risk Loci
Oleg Stens¹, Vivian Trang², Steven Cao², Robert Terkeltaub¹ and Rany Salem², ¹University of California San Diego School of Medicine, La Jolla, CA, ²University of California San Diego School of Public Health, La Jolla, CA
Background/Purpose: Gout is a complex disease involving changes in urate biology and inflammatory responses, and is associated with comorbidities including metabolic syndrome and cardiorenal disease.…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 1909 • ACR Convergence 2021
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: Literature has shown poor adherence to antimalarial (AM) medications in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with the percentage of adherers…
Abstract Number: 0132 • ACR Convergence 2021
Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
Jesse Dabit¹, Mehmet Hocaoglu², Maria Valenzuela-Almada³, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Rachel Giblon¹, Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune multiorgan disease associated with significant morbidity and mortality. Although the survival rate for SLE patients has…

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.